A1 Refereed original research article in a scientific journal
Immune Thrombocytopenia in Finnish Children and Adolescents : A Population-Based Cohort Study
Authors: Kulmala, Lauri-Matti; Aarnivala, Henri; Pokka, Tytti; Huurre, Anu; Järvelä, Liisa; Palmu, Sauli; Pöyhönen, Tuuli; Niinimäki, Riitta
Publisher: WILEY
Publishing place: HOBOKEN
Publication year: 2025
Journal: Acta Paediatrica
Journal name in source: ACTA PAEDIATRICA
Journal acronym: ACTA PAEDIATR
Number of pages: 8
ISSN: 0803-5253
eISSN: 1651-2227
DOI: https://doi.org/10.1111/apa.70090
Web address : https://doi.org/10.1111/apa.70090
Aim
Immune thrombocytopenia (ITP) is the most common cause of thrombocytopenia in children. This study aimed to describe the diagnostics, patient characteristics, and treatment strategies regarding children with ITP, as well as identify risk factors for chronic disease.
Methods
This study included 403 Finnish children aged under 16 years at diagnosis, who were first diagnosed with ITP between 2006 and 2020.
Results
Of the 367/403 patients with complete follow-up data, 242 (65.9%) recovered within three months. Chronic ITP developed in 25.9% of the children. Severe bleeding events occurred in 3.7% of them, with no intracranial bleeding events or deaths reported. Pharmacological treatment was administered to 40.2% of the patients. An elevated risk of chronic ITP was found in the children presenting with an insidious disease onset, female gender, higher age, higher platelet counts, and an absence of recent viral infections. As many as 83.3% of the patients with an insidious disease onset and no recent infections developed chronic ITP.
Conclusion
Most of the children with ITP experienced short and uncomplicated disease courses. Chronic illness was more likely when the disease onset was insidious, the platelet count was not extremely low, and there was no recent history of an infection.
Funding information in the publication:
This work was supported by Lasten Syöpäsäätiö Väre, AAMU Suomen Lasten Syöpäsäätiö and Stiftelsen Alma och K. A. Snellman Säätiö.